Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium 1

3895 - Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer


20 Oct 2018


Presidential Symposium 1


Cytotoxic Therapy

Tumour Site

Breast Cancer


Zefei Jiang


Z. Jiang1, W. Li2, X. Hu3, Q. Zhang4, T. Sun5, S. Cui6, S. Wang7, Q. Ouyang8, Y. Yin9, C. Geng10, Z. Tong11, Y. Cheng12, Y. Pan13, Y. Sun14, H. Wang15, T. Ouyang16, K. Gu17, J. Feng18, X. Wang19

Author affiliations

  • 1 Department Of Breast Cancer, 307th Hospital of PLA (AMMS China), 100071 - Beijing/CN
  • 2 Department Of Cancer, the first hospital of Jilin University, 130021 - changchun/CN
  • 3 Department Of Cancer, fudan university shanghai cancer center, 200032 - shanghai/CN
  • 4 Department Of Cancer, harbin medical university cancer hospital, 150081 - harbin/CN
  • 5 Department Of Cancer, liaoning cancer hospital, 110042 - shenyang/CN
  • 6 Department Of Cancer, henan cancer hospital, 450000 - zhengzhou/CN
  • 7 Department Of Cancer, sun yat-sen university cancer center, 510060 - guangzhou/CN
  • 8 Department Of Cancer, hunan cancer hospital, 410000 - changsha/CN
  • 9 Department Of Cancer, jiangsu province hospital, 210029 - nanjing/CN
  • 10 Department Of Cancer, tumor hospital of hebei province, 050011 - shijiazhuang/CN
  • 11 Department Of Cancer, tianjin medical university cancer hospital, 300060 - tianjin/CN
  • 12 Department Of Cancer, jilin cancer hospital, 130000 - changchun/CN
  • 13 Department Of Cancer, anhui province hospital, 230001 - hefei/CN
  • 14 Department Of Cancer, jinan cance hospital, 250013 - jinan/CN
  • 15 Department Of Cancer, the third hospital of nanchang, 330009 - nanchang/CN
  • 16 Department Of Cancer, beijing cancer hospital, 100142 - beijing/CN
  • 17 Department Of Cancer, the first affiliated hospital of anhui medical university, 230022 - hefei/CN
  • 18 Department Of Cancer, jiangsu cancer hospital, 210009 - nanjing/CN
  • 19 Department Of Cancer, zhejiang cancer hospital, 310022 - hangzhou/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3895


Chidamide (CS055/Tucidinostat/Epidaza®) is an oral subtype-selective HDAC inhibitor. An exploratory clinical study has demonstrated the encouraging antitumor activity of chidamide in combination with exemestane in hormone receptor (HR)-positive advanced breast cancer (ABC) patients.


This randomized, double-blind, placebo controlled study involved postmenopausal patients with HR-positive, HER2-negative ABC failed to tamoxifen and/or nonsteroidal aromatase inhibitor. Eligible patients were randomly assigned (2:1) to two arms (chidamide 30 mg twice a week plus exemestane 25 mg daily or placebo plus exemestane). The primary endpoint was progression-free survival (PFS), assessed by investigator. Secondary endpoints were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and safety.


365 patients were enrolled at 22 centers in China, with 244 in the chidamide group and 121 in the placebo group. The median PFS was 7.4 months (95% confidence interval [CI], 5.5 to 9.2) with chidamide–exemestane and 3.8 months (95% CI, 3.7 to 5.5) with placebo–exemestane (hazard ratio for disease progression or death, 0.755; 95% CI, 0.582 to 0.978; P=0.0336). ORR was 18.4% and 9.1%(P=0.026), and CBR was 46.7% and 35.5%(P=0.034)in the chidamide group and placebo group, respectively. Overall survival results were not mature at the time of the analysis. The most common grade 3 or 4 adverse events (AE) in the chidamide group were neutropenia (50.8% vs. 2.5% in the placebo group), thrombocytopenia (27.5% vs. 2.5%), and leucopenia (18.8% vs. 2.5%). Serious adverse events occurred in 51 (20.9%) patients in the chidamide group and 7 (5.8%) patients in the placebo group. No treatment related death was reported.


This is the first oral HDAC inhibitor combined with exemestane in a pivotal clinical study to demonstrate PFS benefit and manageable adverse effect in HR–positive ABC patients progressed after prior endocrine therapy.

Clinical trial identification


Editorial Acknowledgement

The authors thank B. Wang, T. Liu, and J. Gao for their contributions to the study

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.